The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy
Standard
The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy. / Schmid, Marianne; Hansen, Jens; Rink, Michael; Fisch, Margit; Chun, Felix.
In: BIOMARK MED, Vol. 7, No. 6, 01.12.2013, p. 843-50.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy
AU - Schmid, Marianne
AU - Hansen, Jens
AU - Rink, Michael
AU - Fisch, Margit
AU - Chun, Felix
PY - 2013/12/1
Y1 - 2013/12/1
N2 - A main limitation of early prostate cancer (PCa) detection due to elevated PSA levels is caused by the low specificity of PSA, which is associated with a high proportion of men detected with nonmalignant findings at first or subsequent prostate biopsy (PBX). Multivariate prediction models, such as nomograms, have been developed, providing a more accurate method to prospectively determine the risk of a positive PBX. Combining established clinical risk factors with novel diagnostic markers of PCa appears promising to further improve predictive accuracy estimates. Ideally, these nomograms should be capable of identifying PCa at PBX without missing men with high-grade PCa, and preventing a significant proportion of men without, or with insignificant, PCa from undergoing PBX. The intention is to reduce disease morbidity and mortality by detecting significant PCa at an early stage, and at the same time to avoid overdiagnosis as well as overintervention.
AB - A main limitation of early prostate cancer (PCa) detection due to elevated PSA levels is caused by the low specificity of PSA, which is associated with a high proportion of men detected with nonmalignant findings at first or subsequent prostate biopsy (PBX). Multivariate prediction models, such as nomograms, have been developed, providing a more accurate method to prospectively determine the risk of a positive PBX. Combining established clinical risk factors with novel diagnostic markers of PCa appears promising to further improve predictive accuracy estimates. Ideally, these nomograms should be capable of identifying PCa at PBX without missing men with high-grade PCa, and preventing a significant proportion of men without, or with insignificant, PCa from undergoing PBX. The intention is to reduce disease morbidity and mortality by detecting significant PCa at an early stage, and at the same time to avoid overdiagnosis as well as overintervention.
U2 - 10.2217/bmm.13.114
DO - 10.2217/bmm.13.114
M3 - SCORING: Journal article
C2 - 24266817
VL - 7
SP - 843
EP - 850
JO - BIOMARK MED
JF - BIOMARK MED
SN - 1752-0363
IS - 6
ER -
